


5

CLAIMS

What is claimed is:

1. A compound comprising



10

or a pharmaceutically acceptable salt or a prodrug thereof,

wherein a dashed line indicates the presence or absence of a bond, and an (H)


represents a hydrogen atom which is present if required by said bond;

Y is selected from the group consisting of CO<sub>2</sub>H, CONMe<sub>2</sub>, CONHMe,

15 CONHEt, CON(OCH<sub>3</sub>)CH<sub>3</sub>, CONH<sub>2</sub>, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>,

CONH(CH<sub>2</sub>CH<sub>2</sub>OH), CH<sub>2</sub>OH, P(O)(OH)<sub>2</sub>, CONHSO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>NH<sub>2</sub>,


SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, SO<sub>2</sub>NH(CH<sub>3</sub>),



R is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen,


20 CO<sub>2</sub>H, OH, COH, COCH<sub>3</sub>, COCF<sub>3</sub>, NO<sub>2</sub>, CN, and CF<sub>3</sub>.

2. The compound of claim 1 comprising




or a pharmaceutically acceptable salt or a prodrug thereof.

- 5 3. The compound of claim 2 comprising




or a pharmaceutically acceptable salt or a prodrug thereof.

4. The compound of claim 3 consisting of




- 10 5. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

- 5 6. A compound having an  $\omega$  chain comprising




or a derivative thereof,

wherein a dashed line indicates the presence or absence of a bond, and an (H) represents a hydrogen atom which is present if required by said bond;

- 10 wherein said derivative has a structure as shown above except that an alteration is made to said structure, wherein an alteration consists of

- a. adding, removing, or substituting a non-hydrogen atom of the  $\omega$  chain;
- b. converting a  $\text{CO}_2\text{H}$  to a moiety selected from the group consisting of



- c. converting a phenyl moiety to a pyridinyl, furyl, thienyl, or *n*-butyl moiety; or
- d. adding a substituent comprising from 1 to 3 non-hydrogen atoms to a phenyl moiety;

or a pharmaceutically acceptable salt or a prodrug thereof.

7. The compound of claim 1 comprising
- 25 4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid methyl ester, or

5 4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid,


or a pharmaceutically acceptable salt or a prodrug thereof.

8. The compound of claim 1 consisting of

4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid methyl ester, or

4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid.


9. A method comprising administering an effective amount of a compound to a mammal, said method being effective in treating or preventing glaucoma or  
15 intraocular hypertension, wherein said compound comprises



or a pharmaceutically acceptable salt or a prodrug thereof,


wherein a dashed line indicates the presence or absence of a bond, and an (H) represents a hydrogen atom which is present if required by said bond;

20 Y is selected from the group consisting of CO<sub>2</sub>H, CONMe<sub>2</sub>, CONHMe, CONHEt, CON(OCH<sub>3</sub>)CH<sub>3</sub>, CONH<sub>2</sub>, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, CONH(CH<sub>2</sub>CH<sub>2</sub>OH), CH<sub>2</sub>OH, P(O)(OH)<sub>2</sub>, CONHSO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, SO<sub>2</sub>NH(CH<sub>3</sub>),



25 R is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, CO<sub>2</sub>H, OH, COH, COCH<sub>3</sub>, COCF<sub>3</sub>, NO<sub>2</sub>, CN, and CF<sub>3</sub>.

10. A liquid composition comprising an effective amount of a compound having an  $\omega$  chain comprising



5

or a derivative thereof,

wherein a dashed line indicates the presence or absence of a bond, and an (H)


represents a hydrogen atom which is present if required by said bond;

wherein said derivative has a structure as shown above except that an alteration is

made to said structure, wherein an alteration consists of

- a. adding, removing, or substituting a non-hydrogen atom of the  $\omega$  chain;
- b. converting a  $\text{CO}_2\text{H}$  to a moiety selected from the group consisting of  $\text{CONMe}_2$ ,  $\text{CONHMe}$ ,  $\text{CONHEt}$ ,  $\text{CON}(\text{OCH}_3)\text{CH}_3$ ,  $\text{CONH}_2$ ,  $\text{CON}(\text{CH}_2\text{CH}_2\text{OH})_2$ ,  $\text{CONH}(\text{CH}_2\text{CH}_2\text{OH})$ ,  $\text{CH}_2\text{OH}$ ,  $\text{P}(\text{O})(\text{OH})_2$ ,  $\text{CONHSO}_2\text{CH}_3$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{SO}_2\text{N}(\text{CH}_3)_2$ ,  $\text{SO}_2\text{NH}(\text{CH}_3)$ ,

15



, and

- c. converting a phenyl moiety to a pyridinyl, furyl, thienyl, or *n*-butyl moiety; or

- d. adding a substituent comprising from 1 to 3 non-hydrogen atoms to a phenyl moiety;

20

or a pharmaceutically acceptable salt or a prodrug thereof; and

wherein said composition is intended for topical ophthalmic use.

25